Chitosan/pshRNA Plasmid Nanoparticles Targeting MDR1 Gene Reverse Paclitaxel Resistance in Ovarian Cancer Cells
10.1007/s11596-009-0221-2
- Author:
YANG YAN
1
;
WANG ZEHUA
;
LI MINFANG
;
LU SHI
Author Information
1. Department of Obstetrics and Gynecology,Union Hospital,Tong]i Medical College,Huazhong University of Science and Technology,Wuhan 430022,China
- Keywords:
MDR1 gene;
chitosan;
pshRNA;
ovarian cancer;
paclitaxel;
drug resistance
- From:
Journal of Huazhong University of Science and Technology (Medical Sciences)
2009;29(2):239-242
- CountryChina
- Language:Chinese
-
Abstract:
In order to investigate the effect of chitosan/pshR.NA plasmid nanoparticles targeting MDRI genes on the resistance of A2780/TS cells to paclitaxel,chitosan/pshRNA plasmid nanoparticles were synthesized by means of a complex coacervation technique and transfected into A2780/TS cells.The cells transfected with MDR1-targeted chitosan/pshRNA plasmid nanoparticles were experimental cells and the cells transfected with chitosan/pGPU6/GFP/Neo no-load plasmid nanoparticles served as negative control cells.Morphological features of the nanoparticles were observed under transmission electron microscope (TEM).MDR1 mRNA expression was assessed by RT-PCR.Half-inhibitory concentration (IC50) of paclitaxel for A2780/TS cells was determined by MTT method.TEM showed that the nanoparticles were round-shaped,smooth in surface and the diameters varied from 80 to 120 nm.The MDR1 mRNA in the transfected cells was significantly decreased by 17.6%,27.8% and 52.6% on the post-transfection day 2,4 and 7 when compared with that in A2780/TS cells control (P<0.05).MTT assay revealed that the relative reversal efficiency was increased over time and was 29.6%,51.2% and 61.3% respectively in the transfected cells 2,4,7 days after transfection and IC50 (0.197±0.003,0.144±0.001,0.120±0.004) were decreased with difference being significant when compared with that in A2780/TS (0.269±0.003) cells control (P<0.05).It was concluded that chitosan/pshRNA plasmid nanoparticles targeting MDR1 can effectively reverse the paclitaxel resistance in A2780/TS cells in a time-dependent manner.
